{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:21:27Z","timestamp":1777036887010,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"am","delay-in-days":300,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008460","name":"National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","award":["R01 AT010773"],"award-info":[{"award-number":["R01 AT010773"]}],"id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA048153"],"award-info":[{"award-number":["R01 DA048153"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 DA052690"],"award-info":[{"award-number":["R21 DA052690"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.neuropharm.2024.110216","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T01:55:46Z","timestamp":1731722146000},"page":"110216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The synthetic cannabinoid agonist WIN 55,212-2 reduces experimental pruritus via CB2 receptor activation"],"prefix":"10.1016","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-6519","authenticated-orcid":false,"given":"Antonio Matt","family":"Reck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0688-8210","authenticated-orcid":false,"given":"David P.","family":"Siderovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-1700","authenticated-orcid":false,"given":"Steven G.","family":"Kinsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neuropharm.2024.110216_bib1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2020.01.036","article-title":"Cannabinoids for the treatment of chronic pruritus: a review","volume":"82","author":"Avila","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.neuropharm.2024.110216_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.physbeh.2014.06.003","article-title":"\u03b2-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice","volume":"135","author":"Bahi","year":"2014","journal-title":"Physiol. Behav."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110216_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nn.3619","article-title":"Why we scratch an itch: the molecules, cells and circuits of itch","volume":"17","author":"Bautista","year":"2014","journal-title":"Nat. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110216_bib4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ced.13398","article-title":"Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist","volume":"43","author":"Bilir","year":"2018","journal-title":"Clin. Exp. Dermatol."},{"issue":"26","key":"10.1016\/j.neuropharm.2024.110216_bib5","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1523\/JNEUROSCI.3936-06.2007","article-title":"Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants","volume":"27","author":"Corbill\u00e9","year":"2007","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110216_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0091-3057(00)00477-9","article-title":"Cannabinoids of diverse structure inhibit two DOI-induced 5-HT2A receptor-mediated behaviors in mice","volume":"68","author":"Darmani","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110216_bib8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1006\/mcne.2000.0844","article-title":"Cannabinoid CB1 receptor expression in rat spinal cord","volume":"15","author":"Farquhar-Smith","year":"2000","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110216_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fphar.2020.00359","article-title":"Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors","volume":"11","author":"Finlay","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110216_bib10","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0040-4020(01)99446-3","article-title":"Hashish\u2014VII: the isomerization of cannabidiol to tetrahydrocannabinols","volume":"22","author":"Gaoni","year":"1966","journal-title":"Tetrahedron"},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110216_bib11","first-page":"473","article-title":"Role of nitric oxide in the antipruritic effect of WIN 55,212-2, a cannabinoid agonist","volume":"11","author":"Gercek","year":"2020","journal-title":"Basic Clin. Neurosci."},{"issue":"26","key":"10.1016\/j.neuropharm.2024.110216_bib12","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1073\/pnas.0803601105","article-title":"Beta-caryophyllene is a dietary cannabinoid","volume":"105","author":"Gertsch","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2024.110216_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000371890","article-title":"S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission","volume":"95","author":"Haruna","year":"2015","journal-title":"Pharmacology"},{"key":"10.1016\/j.neuropharm.2024.110216_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.702675","article-title":"Pharmacological properties, therapeutic potential and molecular mechanisms of JWH133, a CB2 receptor-selective agonist","volume":"12","author":"Hashiesh","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2024.110216_bib15","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1021\/ja00960a056","article-title":"Isolation of trans-\u03b46-tetrahydrocannabinol from marijuana","volume":"88","author":"Hively","year":"1966","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110216_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cpt1973143353","article-title":"Delta-8- and delta-9-tetrahydrocannabinol; Comparison in man by oral and intravenous administration","volume":"14","author":"Hollister","year":"1973","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110216_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International union of pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2024.110216_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.apha.2017.03.007","article-title":"CB1 & CB2 receptor pharmacology","volume":"80","author":"Howlett","year":"2017","journal-title":"Adv. Pharmacol."},{"issue":"13","key":"10.1016\/j.neuropharm.2024.110216_bib19","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1038\/npp.2015.148","article-title":"A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with No psychoactive effects","volume":"40","author":"Ignatowska-Jankowska","year":"2015","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110216_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuroscience.2009.06.016","article-title":"Nalfurafine prevents 5\u2032-guanidinonaltrindole- and compound 48\/80-induced spinal c-fos expression and attenuates 5\u2032-guanidinonaltrindole-elicited scratching behavior in mice","volume":"163","author":"Inan","year":"2009","journal-title":"Neuroscience"},{"issue":"18","key":"10.1016\/j.neuropharm.2024.110216_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814328","article-title":"Epicutaneous sensitization to the phytocannabinoid \u03b2-caryophyllene induces pruritic inflammation","volume":"24","author":"Inan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.neuropharm.2024.110216_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/biom9080326","article-title":"\u03b2-Caryophyllene mitigates collagen antibody induced arthritis (CAIA) in mice through a cross-talk between CB2 and PPAR-\u03b3 receptors","volume":"9","author":"Irrera","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuropharm.2024.110216_bib23","volume":"vol. 8","author":"Janoyan","year":"2002"},{"key":"10.1016\/j.neuropharm.2024.110216_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neubiorev.2018.12.026","article-title":"Progress in brain cannabinoid CB2 receptor Research: from genes to behavior","volume":"98","author":"Jordan","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"0","key":"10.1016\/j.neuropharm.2024.110216_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejphar.2013.06.001","article-title":"Acute \u03949-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in mice","volume":"715","author":"Kinsey","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110216_bib26","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/jpet.109.155465","article-title":"Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain","volume":"330","author":"Kinsey","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"s1","key":"10.1016\/j.neuropharm.2024.110216_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2826.2008.01671.x","article-title":"Cannabinoid receptors: where they are and what they do","volume":"20","author":"Mackie","year":"2008","journal-title":"J. Neuroendocrinol."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110216_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2222.2011.03791.x","article-title":"Basic mechanisms of itch","volume":"42","author":"Potenzieri","year":"2012","journal-title":"Clin. Exp. Allergy : Journal of the British Society for Allergy and Clinical Immunology"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110216_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1476-5381.1970.tb10354.x","article-title":"Mechanisms of histamine release by compound 48\/80","volume":"38","author":"Rothschild","year":"1970","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110216_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/can.2019.0016","article-title":"Absence of entourage: terpenoids commonly found in cannabis sativa do not modulate the functional activity of \u03b49-THC at human CB1 and CB2 receptors","volume":"4","author":"Santiago","year":"2019","journal-title":"Cannabis and Cannabinoid Research"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110216_bib32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/jpet.108.150136","article-title":"Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus","volume":"329","author":"Schlosburg","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110216_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00213-011-2224-5","article-title":"CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action","volume":"216","author":"Schlosburg","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110216_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2014.10.002","article-title":"Anti-pruritic activity of pioglitazone on serotonin-induced scratching in mice: possible involvement of PPAR-gamma receptor and nitric oxide","volume":"744","author":"shafizadeh","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110216_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9625936","article-title":"Pruritus: progress toward pathogenesis and treatment","volume":"2018","author":"Song","year":"2018","journal-title":"BioMed Res. Int."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110216_bib36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: a position paper of the international forum for the study of itch","volume":"87","author":"St\u00e4nder","year":"2007","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.neuropharm.2024.110216_bib37","series-title":"Cannabinoids","first-page":"327","article-title":"Effects of cannabinoids on neurotransmission","author":"Szabo","year":"2005"},{"issue":"15","key":"10.1016\/j.neuropharm.2024.110216_bib38","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1111\/bph.15865","article-title":"Review of delta-8-tetrahydrocannabinol (\u03948-THC): comparative pharmacology with \u03949-THC","volume":"179","author":"Tagen","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110216_bib39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0014-2999(74)90125-3","article-title":"Tolerance to the hypothermic and aggression-attenuating effect of \u03948- and \u03949-tetrahydrocannabinol in mice","volume":"28","author":"Ten Ham","year":"1974","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110216_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00702-014-1251-x","article-title":"Attenuation of serotonin-induced itch responses by inhibition of endocannabinoid degradative enzymes, fatty acid amide hydrolase and monoacylglycerol lipase","volume":"122","author":"Tosun","year":"2015","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2024.110216_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pbb.2018.12.009","article-title":"CB1 positive allosteric modulation attenuates \u03949-THC withdrawal and NSAID-induced gastric inflammation","volume":"177","author":"Trexler","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.neuropharm.2024.110216_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109640","article-title":"Assessment of dependence potential and abuse liability of \u03948-tetrahydrocannabinol in mice","volume":"240","author":"Vanegas","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110216_bib42","article-title":"Anti-arthritic and anti inflammatory activity of beta caryophyllene against freund\u2019s complete adjuvant induced arthritis in wistar rats","volume":"1","author":"Vijayalaxmi","year":"2015","journal-title":"Bone Rep Recommendations"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110216_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-009-1592-6","article-title":"Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats","volume":"206","author":"Ward","year":"2009","journal-title":"Psychopharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082400385X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082400385X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T20:59:54Z","timestamp":1733691594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082400385X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":42,"alternative-id":["S002839082400385X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110216","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The synthetic cannabinoid agonist WIN 55,212-2 reduces experimental pruritus via CB2 receptor activation","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110216"}}